Vaccine potential of Mycobacterium tuberculosis-specific genomic regions: In vitro studies in humans

Expert Review of Vaccines

Volumn 8, Issue 10, 2009, Pages 1309-1312

  Mustafa, Abu Salim ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BCG VACCINE; CROSS REACTING ANTIGEN; ESXO ANTIGEN; ESXP ANTIGEN; ESXV ANTIGEN; ESXW ANTIGEN; HEAT SHOCK PROTEIN; PPE68 ANTIGEN; RD1 PEPTIDE; RD12 PEPTIDE; RD13 PEPTIDE; RD15 PEPTIDE; RD4 PEPTIDE; RD7 PEPTIDE; RD9 PEPTIDE; UNCLASSIFIED DRUG;

BACTERIAL GENOME; BCG VACCINATION; CELLULAR IMMUNITY; CLINICAL TRIAL; DEVELOPING COUNTRY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; IN VITRO STUDY; INFECTION CONTROL; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; TUBERCULOSIS;

ANTIGENS, BACTERIAL; DISEASE OUTBREAKS; GENOME, BACTERIAL; HUMANS; IMMUNITY, CELLULAR; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, SUBUNIT;

EID: 70349900719     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.93     Document Type: Editorial

References (44)

1. Global tuberculosis control: epidemiology, strategy, financing. WHO Report 2009. WHO/HTM/TB/2009.411.
2. Smith R. Eradication of tuberculosis by 2050 impossible without new vaccine. Br. Med. J. 338, bl291 (2009).
3. Crampin AC, Glynn JR, Fine PE. What has Karonga taught us? Tuberculosis studied over three decades. Int. J. Tuberc. Lung Dis. 13, 153-164 (2009).
4. Andersen P, Doherty TM. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 3, 656-662 (2005).
5. Hesseling AC, Rabie H, Marais BJ et al. Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin. Infect. Dis. 42, 548-558 (2006).
6. Dockrell HM. Real vaccines in the real world: tuberculosis vaccines move south. Expert Rev. Vaccines 7(6), 703-707 (2008).
7. Triccas JA, Nambiar JK. Challenge of developing new tuberculosis vaccines to generate life-long protective immunity. Expert Rev. Vaccines 8(7), 823-825 (2009).
8. Ly LH, McMurray DN. Tuberculosis: vaccines in the pipeline. Expert Rev. Vaccines 7(5), 635-650 (2008).
9. Skeiky YA, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat. Rev. Microbiol. 4, 469-476 (2006).
10. Mustafa AS. Progress towards the development of new anti-tuberculosis vaccines. In: Focus on Tuberculosis Research. Smith LT (Ed.). Nova Science Publishers, Inc., NY, USA, 47-76 (2005).
11. Aagaard C, Dietrich J, Doherty M, Andersen P. TB vaccines: current status and future perspectives. Immunol. Cell Biol. 87, 279-286 (2009).
12. Hawkridge T, Scriba TJ, Gelderbloem S et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J. Infect. Dis. 198, 544-552 (2008).
13. Behr MA, Wilson MA, Gill WP et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284, 1520-1523 (1999). • Sixteen genomic regions of Mycobacterium tuberculosis, known as regions of difference (RD), are deleted/ lacking in some or all strains of bacillus Calmette-Guérin.
14. de Jonge MI, Brosch R, Brodin P, Demangel C, Cole ST. Tuberculosis: from genome to vaccine. Expert Rev. Vaccines 4(4), 541-1451 (2005).
15. Mustafa AS. Mycobacterial gene cloning and expression, comparative genomics, bioinformatics and proteomics in relation to the development of new vaccines and diagnostic reagents. Med. Princ. Pract. 14(Suppl. 1), 27-34 (2005).
16. Mustafa AS. Biotechnology in the development of new vaccines and diagnostic reagents against tuberculosis. Curr. Pharm. Biotechnol. 2, 157-173 (2001).
17. Mustafa AS. Development of new vaccines and diagnostic reagents against tuberculosis. Mol. Immunol. 39, 113-119 (2002).
18. Mustafa AS. Recombinant and synthetic peptides to identify Mycobacterium tuberculosis antigens and epitopes of diagnostic and vaccine relevance. Tuberculosis (Edinb.) 85,367-376 (2005).
19. Mustafa AS, Al-Attiyah R. Tuberculosis: looking beyond BCG vaccines. J. Postgrad. Med. 49, 134-140 (2003). • Th1 cytokines, dominated by IFN-γ secretion, are considered principal mediators of protective immunity against TB.
20. Flynn J. Immunology of tuberculosis and implications in vaccine development. Tuberculosis 4, 93-101 (2004). (Pubitemid 38087953)
21. Al-Attiyah R, Madi N, El-Shamy AS et al. Cytokine profiles in tuberculosis patients and healthy subjects in response to complex and single antigens of Mycobacterium tuberculosis. FEMS Immunol. Med. Microbiol. 47, 254-261 (2006).
22. Bai X, Wilson SE, Chmura K, Feldman NE, Chan ED. Morphometric analysis of Th(1) and Th(2) cytokine expression in human pulmonary tuberculosis. Tuberculosis 84, 375-385 (2004).
23. Jo E-L, Park J-K, Dockrell HM. Dynamics of cytokine generation in patients with active pulmonary tuberculosis. Curr. Opin. Infect. Dis. 16, 205-210 (2003).
24. Liebeschuétz S, Bamber S, Ewer K et al. Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet 364, 2196-2203 (2004). (Pubitemid 40018449)
25. Turner J, Gonzalez-Juarrero M, Ellis DL et al. In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J. Immunol. 169, 6343-6351 (2002).
26. Murray PJ, Wang L, Onufryk C, Tepper RI, Young RA. T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. J. Immunol. 158, 315-321 (1997). (Pubitemid 127483871)
27. Murray PJ, Young RA. Increased antimycobacterial immunity in interleukin-10 deficient mice. Infect. Immun. 67, 3087-3095 (1999).
28. Jamil B, Shahid F, Hasa Z et al. Interferon γ/IL-10 ratio defines the disease severity in pulmonary and extra pulmonary tuberculosis. Tuberculosis 87, 279-287 (2007). • Th2 cytokines are associated with lack of protection, and, in particular, IL-10 is associated with pathogenesis in TB. (Pubitemid 46936246)
29. Sahiratmadja E, Alisjahbana B, de Boer T et al. Dynamic changes in pro- and anti-inflammatory cytokine profiles and γ interferon receptor signaling integrity correlate with tuberculosis disease activity and response to curative treatment. Infect. Immun. 75, 820-829 (2007).
30. + T cells of the Mycobacterium leprae memory repertoire. Infect. Immun. 67, 5683-5689 (1999).
31. + T-cell lines. Infect. Immun. 68, 3933-3940 (2000).
32. Al-Attiyah R, Mustafa AS. Computer-assisted prediction of HLA-DR binding and experimental analysis for human promiscuous Th1-cell peptides in the 24 kDa secreted lipoprotein (LppX) of Mycobacterium tuberculosis. Scand. J. Immunol. 59, 16-24 (2004).
33. Al-Attiyah R, Mustafa AS, Abal AT et al. In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis. Clin. Exp. Immunol. 138, 139-144 (2004).
34. Mustafa AS, Abal AT, Shaban F, El-Shamy AM, Amoudy HA. HLA-DR binding prediction and experimental evaluation of T-cell epitopes of mycolyl transferase 85B (Ag85B), a major secreted antigen of Mycobacterium tuberculosis. Med. Princ. Pract. 14, 140-146 (2005).
35. Mustafa AS. Th1 cell reactivity and HLA-DR binding prediction for promiscuous recognition of MPT63 (Rv1926c), a major secreted protein of Mycobacterium tuberculosis. Scand. J. Immunol. 69, 213-222 (2009).
36. Mustafa AS. HLA-promiscuous Th1-cell reactivity of MPT64 (Rv1980c), a major secreted antigen of Mycobacterium tuberculosis, in healthy subjects. Med. Princ. Pract. 18, 385-392 (2009).
37. Al-Attiyah R, Mustafa AS. Characterization of human cellular immune responses to novel Mycobacterium tuberculosis antigens encoded by genomic regions absent in Mycobacterium bovis BCG. Infect. Immun. 76, 4190-4198 (2008). •• The highest Th1 responses were induced by RDl peptides and the highest Th2 responses were induced by RD12 and RD13 peptides. Moreover, a strong Th1 bias was observed with peptides of RD1, RD7 and RD9, whereas a strong Th2 bias was seen with peptides of RD12 and RDI3.
38. Mustafa AS, Al-Attiyah R. Identification of Mycobacterium tuberculosis-specific genomic regions encoding antigens inducing protective cellular immune responses. Indian J. Exp. Biol. 47, 498-504 (2009). •• The highest Th1 responses were induced by RD1 peptides and the highest Th2 responses were induced by RD12 and RD13 peptides. Moreover, a strong Th1 bias was observed with peptides of RD1, RD7 and RD9, whereas a strong Th2 bias was seen with peptides of RD12 and RD13.
39. Al-Attiyah RJ, Mustafa AS. Mycobacterial antigen-induced cell proliferation and Th1 and Th2 cytokine secretion by peripheral blood mononuclear cells of diabetic and non-diabetic tuberculosis patients and Mycobacterium bovis BCG vaccinated healthy subjects. Clin. Exp. Immunol. 158, 64-73 (2009). •• The highest Th1 responses were induced by RD1 peptides and the highest Th2 responses were induced by RD12 and RD13 peptides. Moreover, a strong Th1 bias was observed with peptides of RD1, RD7 and RD9, whereas a strong Th2 bias was seen with peptides of RD12 and RD13.
40. Mustafa AS, Al-Attiyah R. Mycobacterium tuberculosis antigens and peptides as new vaccine candidates and immunodiagnostic reagents against tuberculosis. Kuw. Med. J. 36, 171-176 (2004). •• Further testing of the peptide pools of each protein of RD1, RD7 and RD9 showed that PPE68, ESXA, ESXB, ESXO, ESXP, ESXV and ESXW were the best stimulators of Th1 cells.
41. Hanif SNM, El-Shammy AM, Al-Attiyah R, Mustafa AS. Whole blood assays to identify Th1 cell antigens and peptides encoded by Mycobacterium tuberculosis-specific RD1 genes. Med. Princ. Pract. 17, 244-249 (2008).
42. Mustafa AS, El-Shamy AM, Madi NM, Amoudy HA, Al-Attiyah R. Cell-mediated immune responses to complex and single mycobacterial antigens in tuberculosis patients with diabetes. Med. Princ. Pract. 17, 325-330 (2008).
43. Mustafa AS, Al-Attiyah R, Hanif SNM, Shaban FA. Efficient testing of large pools of Mycobacterium tuberculosis RD1 peptides and identification of major antigens and immunodominant peptides recognized by human Th1 cells. Clin. Vaccine Immunol. 15, 916-924 (2008). •• Further testing of the peptide pools of each protein of RD1, RD7 and RD9 showed that PPE68, ESXA, ESXB, ESXO, ESXP, ESXV and ESXW were the best stimulators of Th1 cells.
44. Zhang H, Shi CH, Xue Y et al. Immune response and protective efficacy induced by fusion protein ESAT6-CFP10 of M. tuberculosis in mice. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 22, 443-446 (2006).